東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Analysis of the patent life of new m...

Seoane-Vazquez, Enrique Carlos.

Linked to FindBook

Google Book

Amazon

博客來

Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001./
Author:	Seoane-Vazquez, Enrique Carlos.
Description:	310 p.
Notes:	Source: Dissertation Abstracts International, Volume: 63-10, Section: B, page: 4620.
Contained By:	Dissertation Abstracts International63-10B.
Subject:	Health Sciences, Pharmacy. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3069208
ISBN:	0493888985

Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001.
Seoane-Vazquez, Enrique Carlos.

Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001. - 310 p.

Source: Dissertation Abstracts International, Volume: 63-10, Section: B, page: 4620.

Thesis (Ph.D.)--University of Minnesota, 2002.

The purpose of this study was to describe and analyze the factors affecting the market exclusivity life of the first and last patents listed in the FDA Orange Book for the first New Drug Application (NDA) of a New Molecular Entity (NME) approved in the U.S. between 1980 and 2001.

ISBN: 0493888985Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001.
LDR:02807nmm 2200313 4500 001 1852396
005 20051230065953.5
008 130614s2002 eng d
020 $a 0493888985
035 $a (UnM)AAI3069208
035 $a AAI3069208
040 $a UnM $c UnM
100 1 $a Seoane-Vazquez, Enrique Carlos. $3 1940255
245 1 0 $a Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001.
300 $a 310 p.
500 $a Source: Dissertation Abstracts International, Volume: 63-10, Section: B, page: 4620.
500 $a Adviser: Stephen W. Schondelmeyer.
502 $a Thesis (Ph.D.)--University of Minnesota, 2002.
520 $a The purpose of this study was to describe and analyze the factors affecting the market exclusivity life of the first and last patents listed in the FDA Orange Book for the first New Drug Application (NDA) of a New Molecular Entity (NME) approved in the U.S. between 1980 and 2001.
520 $a A linear regression analysis model was used to determine the impact of drug characteristics, NDA sponsor characteristics, the size of the drug market, drug regulation and policy status, and the intellectual protection policy on NMEs' patent life. A total of 330 drugs approved between 1980 and 1999 were included in the regression analysis. NMEs approved during the period 2000--2001 were not included in the regression analysis due to lack of complete information on patent extensions requested and awarded. FDA and the U.S. Patent Office were the main sources of data for this study.
520 $a The results of the study demonstrate an increase in post-NDA patent and pediatric exclusivity time of the NMEs included in the study by almost 2 years from the period 1980--1989 to the period 1990--1999. The study also shows an increase in last patent post-NDA time and pediatric exclusivity by 1.5 years from the period 1980--1989 to the period 1990--1999. These results contradict the anecdotal reports often found in the literature which suggest a downward trend in post-NDA patent time in late 1980s and early 1990s.
520 $a Several factors explain the increase in patent protection time in the 1990s versus the patent protection time in the 1980s including: (1) a substantial reduction of the NDA review time, (2) increased pharmaceutical patent extension time, (3) increased pediatric exclusivity time, and (4) changes in statutory term for patents. The reduction in NDA review time is the main factor accounting for the increase in post-NDA statutory patent term time.
590 $a School code: 0130.
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Public Health. $3 1017659
690 $a 0572
690 $a 0573
710 2 0 $a University of Minnesota. $3 676231
773 0 $t Dissertation Abstracts International $g 63-10B.
790 1 0 $a Schondelmeyer, Stephen W., $e advisor
790 $a 0130
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3069208